Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
26.61
+1.79 (7.21%)
Oct 20, 2026, 4:00 PM EDT - Market closed
Stoke Therapeutics Revenue
Stoke Therapeutics had revenue of $9.33M in the quarter ending June 30, 2026, a decrease of -32.51%. This brings the company's total for the last twelve months to $27.59M, down -86.20% year-over-year. In the year 2025, Stoke Therapeutics had annual revenue of $184.42M with 404.50% growth. That makes Stoke Therapeutics the 31,875th largest company in the world by revenue and 4,202nd in the United States.
Revenue (ttm)
$27.59M
Revenue Growth
-86.20%
P/S Ratio
62.24
Revenue / Employee
$162,282
Employees
170
Market Cap
1.72B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 184.42M | 147.87M | 404.50% |
| Dec 31, 2024 | 36.56M | 27.78M | 316.34% |
| Dec 31, 2023 | 8.78M | -3.63M | -29.22% |
| Dec 31, 2022 | 12.41M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immunocore Holdings | 430.78M |
| Vir Biotechnology | 303.23M |
| UroGen Pharma | 188.73M |
| Septerna | 98.88M |
| Intellia Therapeutics | 59.51M |
| Generate Biomedicines | 26.48M |
| Maze Therapeutics | 20.00M |
STOK News
- 4 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 8 days ago - Stoke Therapeutics announces presentations of data for STK-002 - TheFly
- 8 days ago - Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting - Business Wire
- 14 days ago - Stoke Therapeutics announces two presentations of data for STK-002 at AAO - TheFly
- 14 days ago - Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting - Business Wire
- 15 days ago - Stoke completes meeting with FDA to align aspects with NDA for zorevunersen - TheFly
- 15 days ago - Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome - Business Wire
- 27 days ago - Stoke Therapeutics names Bo Cumbo to board of directors - TheFly